Fresh findings on lecanemab to be unveiled at CTAD conference

Written by Emily J. Thompson, Senior Investment Analyst

Source: Yahoo Finance

Updated: Nov 19 2025

0mins

Source: Yahoo Finance

Lecanemab Presentation at CTAD: BioArctic's partner Eisai will present new findings on lecanemab at the Clinical Trials on Alzheimer's Disease (CTAD) conference, focusing on long-term treatment benefits, safety of subcutaneous administration, and real-world clinical data.
Key Oral Presentations: Significant presentations will cover the benefits of continued lecanemab therapy, the potential of subcutaneous dosing, and insights from a post-marketing observational study in Japan.
Poster Presentations: Various poster sessions will highlight enrollment patterns, safety findings, and comparisons of lecanemab with other treatments, showcasing real-world clinical outcomes and patient experiences.
Collaboration Background: Lecanemab, developed through a collaboration between BioArctic and Eisai, is approved in 51 countries and aims to slow Alzheimer's disease progression, with ongoing studies exploring its efficacy in preclinical and dominantly inherited Alzheimer's disease.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.